Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
NEW YORK Bayer’s recent ad claims have become a headache for the German drug company.
The Center for Science in the Public Interest filed a lawsuit yesterday against Bayer regarding claims made on behalf of its Men’s One A Day multivitamin. The product states that because it has selenium, it might reduce the risk of prostate cancer — an assertion CSPI said has been proven false. (Download the complaint)
The nonprofit health advocacy group said it reached out to Bayer in June, asking it to alter its marketing materials following the results of an eight-month clinical trial that showed that selenium does not prevent prostate cancer.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in